Mds New Treatments 2025. Food and drug administration approved tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (r/r) myelodysplastic syndromes (mds) with an. Serving the aplastic anemia, myelodysplastic disease syndromes (mds), paroxysmal nocturnal hemoglobinuria (pnh), and related bone marrow failure disease communities, aamdsif empowers patients and their families, invests.
In a current international trial at 54 sites in 17 countries, researchers tested a new treatment combination in 127 patients. This is probably a tough.
